A gene expression signature predicts survival of patients with stage I non-small cell lung cancer

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• Lung cancer is a leading cause of cancer death, with high recurrence rates in early stages (I and II) non-small cell lung cancer (NSCLC) post-surgery.
• Current methods lack reliable predictors for identifying patients at high risk of recurrence, hindering personalized treatment strategies.

Purpose of the Study:

• To identify a gene expression signature that predicts survival and guides treatment decisions in stage I NSCLC patients.
• To develop a molecular tool for stratifying patients based on recurrence risk.

Main Methods:

• A meta-analysis of seven microarray datasets from NSCLC studies was performed.
• Differential gene expression analysis focused on survival time (under 2 years vs. over 5 years).
• Distance-weighted discrimination (DWD) was used for systematic bias adjustment.

Main Results:

• A consensus set of 4,905 genes was identified, leading to a 64-gene expression signature predictive of treatment benefit.
• Kaplan-Meier analysis confirmed significant differences in overall survival between high- and low-risk groups identified by the signature.
• The 64-gene signature includes genes involved in cancer metastasis and apoptosis.

Conclusions:

• Gene expression signatures from multiple datasets can be reconciled effectively.
• The identified 64-gene signature is a valuable tool for predicting survival in stage I NSCLC.
• This signature has the potential to inform and personalize treatment decisions for lung cancer patients.